{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:47Z","timestamp":1791233087331,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007278","name":"Henry Ford Health System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.02.010","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T16:47:35Z","timestamp":1709138855000},"page":"102059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Gu\u00e9rin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Gu\u00e9rin Treatment"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-524X","authenticated-orcid":false,"given":"Jazzmyne","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lybbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherjeel","family":"Sana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-0156","authenticated-orcid":false,"given":"Ahmed","family":"El-Zawahry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Peabody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Deebajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Dynda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Babaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Crabtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-1472","authenticated-orcid":false,"given":"Kristin","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McVary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-5588","authenticated-orcid":false,"given":"Kathy","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Alanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.02.010_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.02.010_bib0002","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.02.010_bib0003","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical Bacillus Calmette-Guerin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guerin treatment","volume":"39","author":"Alanee","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2024.02.010_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.02.010_bib0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","article-title":"T1 bladder cancer: current considerations for diagnosis and management","volume":"16","author":"Jordan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2024.02.010_bib0006","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","article-title":"Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort","volume":"81","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.02.010_bib0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ucl.2017.12.008","article-title":"Quality of life after radical cystectomy","volume":"45","author":"Tyson","year":"2018","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2024.02.010_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1148\/rg.2019180014","article-title":"Complications of intravesical BCG immunotherapy for bladder cancer","volume":"39","author":"Green","year":"2019","journal-title":"Radiographics"},{"key":"10.1016\/j.clgc.2024.02.010_bib0009","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2147\/DDDT.S146286","article-title":"Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clgc.2024.02.010_bib0010","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.02.010_bib0011","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.02.010_bib0012","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/14737140.2023.2265572","article-title":"Immunotherapy in urothelial cancer: current status and future directions","volume":"23","author":"Piombino","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.clgc.2024.02.010_bib0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/UPJ.0000000000000517","article-title":"Quality of life in the phase 2\/3 trial of N-803 plus bacillus calmette-gu\u00e9rin in bacillus calmette-gu\u00e9rin\u2012unresponsive nonmuscle-invasive bladder cancer","volume":"11","author":"Chamie","year":"2024","journal-title":"Urol Pract"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T07:59:44Z","timestamp":1717660784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000326"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.02.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Gu\u00e9rin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Gu\u00e9rin Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102059"}}